SILODOSIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H32F3N3O4
Molecular Weight	495.5345
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](CC1=CC(C(N)=O)=C2N(CCCO)CCC2=C1)NCCOC3=CC=CC=C3OCC(F)(F)F

InChI

InChIKey=PNCPYILNMDWPEY-QGZVFWFLSA-N

InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/14725494 | https://www.ncbi.nlm.nih.gov/pubmed/7651358

Silodosin is a selective antagonsit of alpha-1a adrenergic receptor which was developed by Kissei Pharmaceutical. The drug was approved by FDA under the name Rapaflo for the treatment of signs and symptoms associated with benign prostatic hyperplasia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Alpha-1a adrenergic receptor 66 Target ID: CHEMBL229 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf	Antagonist 2778		0.32 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Benign prostatic hyperplasia 28 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf	Palliative		Approved 8429	RAPAFLO Approved Use RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Launch Date 2008

C_max

Value	Dose	Co-administered	Analyte	Population
61.6 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf	8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SILODOSIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
373.4 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf	8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SILODOSIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf	8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SILODOSIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
3% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf	8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SILODOSIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
48 mg 1 times / day multiple, oral Highest studied dose Dose: 48 mg, 1 times / day Route: oral Route: multiple Dose: 48 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21114397 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54	healthy, 19 - 45 n = 6 Health Status: healthy Age Group: 19 - 45 Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/21114397 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54	DLT: Postural hypotension... Dose limiting toxicities: Postural hypotension Sources: https://pubmed.ncbi.nlm.nih.gov/21114397 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54
12 mg single, oral Highest studied dose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242	healthy, 23 ± 1.4 n = 8 Health Status: healthy Age Group: 23 ± 1.4 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242	Other AEs: Nervous system disorder NOS, Fatigue... Other AEs: Nervous system disorder NOS (13%) Fatigue (13%) Dizziness (13%) Hematuria (13%) Leukocyturia (13%) Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf Page: p.6	unhealthy n = 466 Health Status: unhealthy Condition: Benign prostatic hyperplasia Sex: M Population Size: 466 Sources: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf Page: p.6	Disc. AE: Retrograde ejaculation... AEs leading to discontinuation/dose reduction: Retrograde ejaculation (2.8%) Sources: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf Page: p.6
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Benign prostatic hyperplasia Sex: M Sources: https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf Page: p.3	Other AEs: Intraoperative floppy iris syndrome... Other AEs: Intraoperative floppy iris syndrome Sources: https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf Page: p.3

AEs

AE	Significance	Dose	Population
Postural hypotension	DLT	48 mg 1 times / day multiple, oral Highest studied dose Dose: 48 mg, 1 times / day Route: oral Route: multiple Dose: 48 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21114397 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54	healthy, 19 - 45 n = 6 Health Status: healthy Age Group: 19 - 45 Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/21114397 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54
Dizziness	13%	12 mg single, oral Highest studied dose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242	healthy, 23 ± 1.4 n = 8 Health Status: healthy Age Group: 23 ± 1.4 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242
Fatigue	13%	12 mg single, oral Highest studied dose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242	healthy, 23 ± 1.4 n = 8 Health Status: healthy Age Group: 23 ± 1.4 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242
Hematuria	13%	12 mg single, oral Highest studied dose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242	healthy, 23 ± 1.4 n = 8 Health Status: healthy Age Group: 23 ± 1.4 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242
Leukocyturia	13%	12 mg single, oral Highest studied dose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242	healthy, 23 ± 1.4 n = 8 Health Status: healthy Age Group: 23 ± 1.4 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242
Nervous system disorder NOS	13%	12 mg single, oral Highest studied dose Dose: 12 mg Route: oral Route: single Dose: 12 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242	healthy, 23 ± 1.4 n = 8 Health Status: healthy Age Group: 23 ± 1.4 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/21804212 Page: p.1242
Retrograde ejaculation	2.8% Disc. AE	8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf Page: p.6	unhealthy n = 466 Health Status: unhealthy Condition: Benign prostatic hyperplasia Sex: M Population Size: 466 Sources: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf Page: p.6
Intraoperative floppy iris syndrome		8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Benign prostatic hyperplasia Sex: M Sources: https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf Page: p.3

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	inhibitor 1767 inducer 389 substrate 1037	inhibitor 1852 substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882	UGT2B7 389 P-gp 1537 CYP1A1 349 CYP1A2 1054 CYP2A6 543 CYP2C19 991 CYP2E1 667 UGT1A1 418 UGT1A3 422 UGT1A6 307 UGT1A9 380 UGT1A10 291 UGT2B15 203	CYP1A2 701 CYP2C8 168 CYP2C19 293 P-gp 257

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP2C8 965	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 12	no
P-gp 1650	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5.0	no	no (co-administration study) Comment: silodosin did not significantly affect the PK of digoxin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5.0

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT1A1 418	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no
UGT1A10 291	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no
UGT1A3 422	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no
UGT1A6 307	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no
UGT1A9 380	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no
UGT2B15 203	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_PharmR_P1.pdf Page: 61.0	no
CYP1A1 349	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no	no (co-administration study) Comment: furafylline did not affect silodosin metabolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no	no (co-administration study) Comment: furafylline did not affect silodosin metabolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0
CYP2A6 543	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no	no (co-administration study) Comment: coumarin did not affect silodosin metabolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no	no (co-administration study) Comment: S-mephenytoin did not affect silodosin metabolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no	no (co-administration study) Comment: sulfafenazole did not affect silodosin metabolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no	no (co-administration study) Comment: quinidine did not affect silodosin metabolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0	no	no (co-administration study) Comment: diethyldithiocarbamate did not affect silodosin metabolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 16.0
UGT2B7 389	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 11.0	yes
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 11, 12	yes	yes (co-administration study) Comment: ketaconzaole increased sildosin Cmax by 3.8-fold and AUC by 3.2-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 5, 11, 12
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 17.0	yes	yes (co-administration study) Comment: ketaconzaole increased sildosin Cmax by 3.8-fold and AUC by 3.2-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_ClinPharmR.pdf Page: 17.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_PharmR_P1.pdf Page: 2, 31

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA001VHU	https://www.aablocks.com/goods/Goods/detail?id=AA001VHU
AK Scientific, Inc. (AKSCI)	66700	http://www.aksci.com/item_detail.php?cat=66700
Aaron Chemicals	AR001W9M	http://www.aaronchem.com/160970-54-7
AbMole Bioscience	M3551	http://www.abmole.com/products/silodosin.html
Achemo Scientific Limited	AC-63538	http://www.achemo.com/search/?Keyword= 160970-54-7
Achemtek	0101-002081	http://www.achemtek.com/160970-54-7
Acorn PharmaTech	ACN-S002529	http://www.acornpharmatech.com/
Active Biopharma	ABP000202	http://www.activebiopharma.com/160970-54-7
Alfa Chemistry	AP160970547	https://reagents.alfa-chemistry.com/product/silodosin-cas-160970-54-7-5943.html
Alfa Chemistry	1051374-52-7	https://www.alfa-chemistry.com/cas_1051374-52-7.htm
Allbio Pharm Co., Ltd	AF15549	http://www.allbiopharm.com/product/n/AF15549
Alsachim	1524	http://www.alsachim.com/product-C2122-glo.bal-view.html
Ambeed	A632990	https://www.ambeed.com/products/160970-54-7.html
Angel Pharmatech	AG-19708	http://www.angelpharmatech.com/160970-54-7.html
ApexBio Technology	A8521	http://www.apexbt.com/silodosin.html
Aurora Fine Chemicals LLC	A24.077.565	http://online.aurorafinechemicals.com/info?ID=A24.077.565
Aurum Pharmatech LLC	W-5225	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5225
AvaChem Scientific	2658	http://www.avachem.com/productSearch.asp?2658
Axon MedChem	3112	https://www.axonmedchem.com/product/3112
BLD Pharm	BD161491	http://www.bldpharm.com/products/160970-54-7.html
BioChemPartner	BCP02143	http://www.biochempartner.com/160970-54-7-BCP02143
BioSynth	Q-102517	https://www.biosynth.com/en/products/chemical-intermediates/advanced-intermediates/products/Q-102517.html
CSNpharm	CSN12335	https://www.csnpharm.com/products/silodosin.html
Chem Scene	CS-0284	http://www.chemscene.com/160970-54-7.html
ChemFaces	CFN90002	http://www.chemfaces.com/natural/Silodosin-CFN90002.html
ChemMol	30116026	http://www.chemmol.com/chemmol/30116026.html
ChemMol	49401385	http://www.chemmol.com/chemmol/49401385.html
Chemspace	CSSB00016998219	https://chem-space.com/CSSB00016998219
Clearsynth	CS-O-11743	https://www.clearsynth.com/en/CSO11743.html
DC Chemicals	DCAPI1485	http://www.dcchemicals.com/product_show-Silodosin.html
Hairui	HR117388	http://www.hairuichem.com/en/product/160970-54-7.html
Lab Network	LN01296344	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01296344
MedChem Express	HY-10122	https://www.medchemexpress.com/Silodosin.html
OChem	24781	http://www.ocheminc.com/index.php?act=psearch&pid=970S649
Renno Tech	RL02066	http://www.rennotech.com/product_show.asp?id=2315
Selleck Chemicals	S1613	http://www.selleckchem.com/products/Silodosin(Rapaflo).html
Sigma-Aldrich	SML2142_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/sml2142?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S543190	http://www.smolecule.com/products/s543190
Synblock Inc	SB19320	http://www.synblock.com/product/160970-54-7.html
THE BioTek	bt-283302	https://www.thebiotek.com/product/inhibitors/bt-283302
Tocris	6663	https://www.tocris.com/products/silodosin_6663
TripleBond	CS0060	http://www.triplebond-canada.com/prod/1593/
VladaChem	VL281883-10MG	https://www.vladachem.com/product.php?products=160970-54-7
abcr GmbH	AB479551	http://www.abcr.com/shop/en/AB479551
iChemical	EBD33557	http://www.ichemical.com/products/160970-54-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.	1995 Aug	7651358
Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats.	2002 Oct	12419883
KMD 3213: KAD 3213, silodosin.	2004	14725494
Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors.	2004 Sep 1	15306222
[Pharmacokinetic profile of silodosin in clinical practice].	2006 Mar	16518091
[Pharmacokinetics and disposition of silodosin (KMD-3213)].	2006 Mar	16518089
Search for new alpha1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia.	2007 Apr	19675810
Alpha1-adrenoceptors and ejaculatory function.	2007 Oct	17603543
Different affinities of native alpha1B-adrenoceptors for ketanserin between intact tissue segments and membrane preparations.	2008 Apr 28	18336813
[Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia].	2008 Dec	19174997
Gateways to clinical trials.	2008 Jun	18806898
The involvement of urothelial alpha1A adrenergic receptor in controlling the micturition reflex.	2008 Oct	18997438
Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.	2008 Oct	18775032
Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography.	2008 Oct	18721206
Computational studies of the binding site of alpha1A-adrenoceptor antagonists.	2008 Oct	18626669
Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters.	2009 Aug	19783871
Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.	2009 Dec	19837428
Gene expressions and mechanical functions of α1-adrenoceptor subtypes in mouse ureter.	2009 Dec	19259685
Silodosin (Rapaflo) for benign prostatic hyperplasia.	2009 Jan 12	19122568
Short- and long-term effects of silodosin, a selective alpha 1A-adrenoceptor antagonist, on ejaculatory function in rats.	2009 Jun	19220259
New drugs: milnacipran hydrochloride, fesoterodine fumarate, and silodosin.	2009 Mar-Apr	19289354
Determination of silodosin in human plasma by liquid chromatography-tandem mass spectrometry.	2009 Nov 1	19782650
Effects of silodosin and naftopidil on the distal ureter and cardiovascular system in anesthetized dogs: comparison of potential medications for distal ureteral stone passage.	2010 Jan	19914658
Gateways to clinical trials.	2010 Jul-Aug	20852754
(RS)-1-(1-Acetyl-indolin-5-yl)-2-chloro-propan-1-one.	2010 Jun 9	21587848
Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.	2010 May	20220748
Gateways to clinical trials.	2010 Nov	21225019
Selective α1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity.	2010 Oct	19834713
Silodosin in the treatment of benign prostatic hyperplasia.	2010 Oct 27	21116335

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 8 mg orally once daily with a meal. The dose can be reduced to 4 mg for those with moderate renal impairment.

Route of Administration: Oral

In Vitro Use Guide

Human prostate tissue were treated with silodosin at 3 uM added 15 min before application of noradrenaline (30 uM) to study the inhibition of noradrenaline-activated Transcription Factors Elk1 and SRF.

Name

Type

Language

SILODOSIN

Official Name

English

RAPAFLO

Brand Name

English

SILODOSIN [ORANGE BOOK]

Common Name

English

KSO-0400

Common Name

English

URIEF

Brand Name

English

SILODOSIN [EMA EPAR]

Common Name

English

(-)-1-(3-HYDROXYPROPYL)-5-((2R)-2-((2-(2-(2,2,2-TRIFLUOROETHOXY)PHENOXY)ETHYL)AMINO)PROPYL)-2,3-DIHYDRO-1H-INDOLE-7-CARBOXAMIDE

Systematic Name

English

2,3-DIHYDRO-1-(3-HYDROXYPROPYL)-5-((2R)-2-((2-(2-(2,2,2-TRIFLUOROETHOXY)PHENOXY)ETHYL)AMINO)PROPYL)-1H-INDOLE-7-CARBOXAMIDE

Systematic Name

English

KAD-3213

Code

English

SILODOSIN [JAN]

Common Name

English

silodosin [INN]

Common Name

English

SILODOSIN [MI]

Common Name

English

SILODYX

Brand Name

English

RAPILIF

Brand Name

English

SILODOSIN [VANDF]

Common Name

English

Silodosin [WHO-DD]

Common Name

English

KMD-3213

Code

English

SILODAL

Brand Name

English

SILODOSIN [MART.]

Common Name

English

UROREC

Brand Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

UROREC (AUTHORIZED: PROSTATIC HYPERPLASIA)